celecoxib,nivolumab,ipilimumab
bms
['niche,(-niche 2),(-niche-2),(-niche2)']
excellent presentation by on the role of yd t-cells in response to immunotherapy in b2m-mutated dmmr tumors, including data from niche #esmo22 
Medical Oncologist, GI cancers @nki_nl neoadjuvant #immunotherapy #cancerresearch. Opinions my own